Lama Nazzal is a Nephrology physician affiliated with NYU Langone Health. OpenAlex indexes 87 publications with 1,353 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
222 E 41st St
New York, NY 100176739
Telephone
646-825-6300Provider last certified this registry record 13 Jun 2023.
Clinical trials
- Gut Kidney Axis in Enteric Hyperoxaluria
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- IDORSIA PHARMACEUTICALS US INCProgram year20241 payment
- Novo Nordisk IncProgram year20241 payment
- Alnylam Pharmaceuticals Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
57.9%Metabolic Alkalinizer20.6%Potassium Citrate Er100%Part D<11 patientsVitamin D3 Analog19%Calcitriol100%Part D<11 patients+ 1 more class in this area
Cardiovascular
29.4%Angiotensin receptor blocker (ARB)15.9%Losartan Potassium100%Part D<11 patientsCalcium channel blocker13.5%Nifedipine Er100%Part D<11 patientsOther
12.7%Drugs for treatment of hyperkalemia and hyperphosphatemia12.7%Lokelma100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- The role of the microbiome and other host related factors in determining urine oxalate levels
New York University School of Medicine
FY2026$728,134R01DK137473 - The role of the microbiome and other host related factors in determining urine oxalate levels
New York University School of Medicine
FY2025$751,588R01DK137473 - Gut-kidney axis in enteric hyperoxaluria
New York University School of Medicine
FY2025$326,423R01DK129675
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Comparison of Plasma Oxalate Measurement Methods in Patients With End-Stage Kidney Disease
Kidney International Reports
2025 - Cardiotoxic Effect of Oxalate on Mitochondrial Function in Cardiomyocytes
Journal of the American Society of Nephrology
2025 - Effect of Microbiome Modulation on Urinary Citrate and pH
Journal of the American Society of Nephrology
2025 - Multiomics Assessment of the Gut Microbiome in Rare Hyperoxaluric Conditions
Kidney International Reports
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”